Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 10615-10625

  Abdel Rahman, Omar ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Bevacizumab; Neuroendocrine neoplasms; Sunitinib; VEGF

Indexed keywords

BEVACIZUMAB; CABOZANTINIB; PAZOPANIB; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER PROGNOSIS; CARCINOGENESIS; CHEMOTHERAPY; DRUG EFFICACY; HUMAN; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; NEUROENDOCRINE TUMORS; PROGNOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEUROENDOCRINE TUMORS; PROGNOSIS; PROTEIN KINASE INHIBITORS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84920948299     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2612-7     Document Type: Review

References (70)

1. Bosman F, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer; 2010.
2. Kloppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2011;18 Suppl 1:S1–S16.
3. Volante M, Righi L, Berruti A, et al. The pathological diagnosis of neuroendocrine tumours: common questions and tentative answers. Virchows Arch. 2011;458:393–402.
4. Modlin I, Moss S, Chung D, et al. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumours. J Natl Cancer Inst. 2008;100:1282–9.
5. Modlin I, Oberg K, Chung D, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61–72.
6. Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol. 2012;8:54–64.
7. Yao J, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumours in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.
8. Aaltonen L, Hamilton S, World Health Organization, International Agency for Research on Cancer. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; Oxford University Press Distributor; 2000.
9. Oberg K, Astrup L, Eriksson B, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II—specific NE tumour types. Acta Oncol. 2004;43:626–36.
10. Oberg K, Astrup L, Eriksson B, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I—general overview. Acta Oncol. 2004;43:617–25.
11. Oberg K, Jelic S. Neuroendocrine gastroenteropancreatic tumours: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:150–3.
12. Plockinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology. 2004;80:394–424.
13. Ramage J, Davies A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54 Suppl 4:iv1–16.
14. Baldelli R, Barnabei A, Rizza L, et al. Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front Endocrinol (Lausanne). 2014;5:7.
15. Lawnicka H, Stepień H, Wyczółkowska J, et al. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun. 2000;268(2):567–71.
16. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–63.
17. http://www.oncuview.tv/portals/0/linkedfiles/GEP-NETS_WHO_Update_Classification.pdf. Accessed 29 May 2014
18. Leung DW, Cachianes G, Kuang. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–9.
19. Tischer E, Gospodarowicz D, Mitchell R, et al. Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family. Biochem Biophys Res Commun. 1989;165:1198–206.
20. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 2006;12:5018–22.
21. Hamerlik P, Lathia JD, Rasmussen R, et al. Autocrine VEGF–VEGFR2–neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med. 2012;209:507–20.
22. Abdel-Rahman O (2014) Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer; preclinical and clinical aspects. Crit Rev Oncol Hematol.
23. Parker MW, Guo HF, Li X, et al. Function of members of the neuropilin family as essential pleiotropic cell surface receptors. Biochemistry. 2012;51:9437–46.
24. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871–82. doi:10.1038/nrc3627.
25. De Mello RA, Costa BM, Reis RM, Hespanhol V. Insights into angiogenesis in non-small cell lung cancer: molecular mechanisms, polymorphic genes, and targeted therapies. Recent Pat Anticancer Drug Discov. 2012;7(1):118–31.
26. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer. 2010;10(7):505–14.
27. Lichtenberger BM, Tan PK, Niederleithner H, et al. Autocrine BVEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell. 2010;140(2):268–79.
28. Alevizakos M, Kaltsas S, Syrigos KN. The VEGF pathway in lung cancer. Cancer Chemother Pharmacol. 2013;72(6):1169–81. doi:10.1007/s00280-013-2298-3. Epub 2013 Oct 2.
29. Fazio N, Abdel-Rahman O, Spada F, Galdy S, De Dosso S, Capdevila J, et al. RAF signaling in neuroendocrine neoplasms: from bench to bedside. Cancer Treat Rev. 2014. doi:10.1016/j.ctrv.2014.06.009.
30. Zhang J, Jia Z, Li Q, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer. 2007;109(8):1478–86.
31. Pavel ME, Hassler G, Baum U, et al. Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas. Clin Endocrinol (Oxf). 2005;62(4):434–43.
32. Pinato DJ, Tan TM, Toussi ST, et al. An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. Br J Cancer. 2014;110(1):115–22. doi:10.1038/bjc.2013.682.
33. Kuiper P, Hawinkels LJ, de Jonge-Muller ES, et al. Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol. 2011;17(2):219–25. doi:10.3748/wjg.v17.i2.219.
34. Poncet G, Villaume K, Walter T, et al. Angiogenesis and tumor progression in neuroendocrine digestive tumors. J Surg Res. 2009;154(1):68–77. doi:10.1016/j.jss.2008.03.055.
35. Takahashi Y, Akishima-Fukasawa Y, Kobayashi N, et al. Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors. Clin Cancer Res. 2007;13(1):187–96.
36. Silva SR, Bowen KA, Rychahou PG, et al. VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis. Int J Cancer. 2011;128(5):1045–56. doi:10.1002/ijc.25441.
37. Marton I, Knezevic F, Ramic S, et al. Immunohistochemical expression and prognostic significance of HIF-1α and VEGF-C in neuroendocrine breast cancer. Anticancer Res. 2012;32(12):5227–32.
38. Abdel-Rahman O, Fouad M. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs); a systematic review of the literature. J Cancer Res Clin Oncol. 2014. doi:10.1007/s00432-014-1757-5.
39. Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib; an updated systematic review and meta-analysis. Expert Rev Anticancer Ther. 2014. doi:10.1586/14737140.2014.894465.
40. Abdel-Rahman O, Fouad M. Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis. Expert Rev Anticancer Ther. 2014;14(9):1063–73.
41. Abdel-Rahman O, Fouad M (2014) Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib; an updated systematic review and comparative meta analysis.Crit Rev Oncol Hematol.
42. Kasuya K, Nagakawa Y, Suzuki M, et al. Anti-vascular endothelial growth factor antibody single therapy for pancreatic neuroendocrine carcinoma exhibits a marked tumor growth-inhibitory effect. Exp Ther Med. 2011;2(6):1047–52.
43. Kasuya K, Nagakawa Y, Suzuki M, et al. Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma. Exp Ther Med. 2012;3(4):599–602.
44. Allen E, Walters IB, Hanahan D. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res. 2011;17(16):5299–310. doi:10.1158/1078-0432.CCR-10-2847.
45. Scholz A, Wagner K, Welzel M, et al. The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model. Gut. 2009;58(2):261–70. doi:10.1136/gut.2007.146415.
46. Berruti A, Fazio N, Ferrero A, et al. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. BMC Cancer. 2014;14(1):184.
47. Chan JA, Stuart K, Earle CC, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012;30(24):2963–8. doi:10.1200/JCO.2011.40.3147.
48. Kulke MH, Chan JA, Meyerhardt JA, et al. A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol. 2011;68(2):293–300. doi:10.1007/s00280-010-1478-7.
49. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008;26(8):1316–23. doi:10.1200/JCO.2007.13.6374.
50. Castellano D, Capdevila J, Sastre J, et al. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). Eur J Cancer. 2013;49(18):3780–7. doi:10.1016/j.ejca.2013.06.042. Epub 2013 Sep 5.
51. Firdaus I, Shih K, Zakari A, et al. Bevacizumab, pertuzumab, and sandostatin for patients (pts) with advanced neuroendocrine cancers (NET). J Clin Oncol. 2012;30(suppl; abstr 4127).
52. Koumarianou A, Antoniou S, Kanakis G, et al. Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. Endocr Relat Cancer. 2012;19(1):L1–4. doi:10.1530/ERC-11-0287. Print 2012 Feb.
53. Strosberg JR, Weber JM, Choi J, et al. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol. 2012;23(9):2335–41. doi:10.1093/annonc/mdr614.
54. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26(20):3403–10. doi:10.1200/JCO.2007.15.9020.
55. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–13. doi:10.1056/NEJMoa1003825.
56. Chan JA, Mayer RJ, Jackson N, et al. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumours. Cancer Chemother Pharmacol. 2013;71(5):1241–6. doi:10.1007/s00280-013-2118-9. Epub 2013 Mar 9.
57. Hobday T, Rubin J, Holen K, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol (Meeting Abstracts). 2007;25(18_suppl 4504).
58. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28(14):2323–30. doi:10.1200/JCO.2009.25.0068. Epub 2010 Apr 5.
59. Quintela-Fandino M, Krzyzanowska M, Duncan G, et al. In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours. Br J Cancer. 2013;108(6):1298–305. doi:10.1038/bjc.2013.64. Epub 2013 Feb 14.
60. Ahn H, Choi J, Kim K, et al. Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours. Br J Cancer. 2013;109(17):1414–9. doi:10.1038/bjc.2013.470.
61. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29(19):2660–6.
62. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–46.
63. Wells SA, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28(5):767–72.
64. Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134–41.
65. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24(3):401–6.
66. Varker KA, Campbell J, Shah MH. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol. 2008;61(4):661–8.
67. Ng CS, Charnsangavej C, Wei W, et al. Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. AJR Am J Roentgenol. 2011;196(3):569–76. doi:10.2214/AJR.10.4455.
68. Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma; a systematic review of the literature. Crit Rev Oncol Hematol. 2014. doi:10.1016/j.critrevonc.2013.12.013.
69. Abdel-Rahman O. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside. J Egypt Natl Canc Inst. 2013;25(4):165–71. doi:10.1016/j.jnci.2013.08.002. Epub 2013 Sep 21.
70. Sennino B, Ishiguro-Oonuma T, Wei Y, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2012;2(3):270–87. doi:10.1158/2159-8290.CD-11-0240.